# A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.

> **NCT00439426** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 25 (actual)

## Conditions studied

- Nasopharyngeal Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** capecitabine [Xeloda]

## Key facts

- **NCT ID:** NCT00439426
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439426, "A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00439426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*